HER2 CISH PHARMDX KIT

FDA Premarket Approval P100024 S007

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Alternate warehouse established within the current facility. The change is being made for the storage of finished devices after they have been qa released.

DeviceHER2 CISH PHARMDX KIT
Generic NameChromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/neu Gene, Breast Cancer
ApplicantDAKO DENMARK A/S
Date Received2015-08-13
Decision Date2015-09-10
PMAP100024
SupplementS007
Product CodeNYQ 
Advisory CommitteePathology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product Yes
Applicant Address DAKO DENMARK A/S 42 Produktionsvej dk-2600 glostrup DK-26-2600

Supplemental Filings

Supplement NumberDateSupplement Type
P100024Original Filing
S013 2017-03-13 30-day Notice
S012 2017-03-13 30-day Notice
S011 2016-12-27 Real-time Process
S010 2016-07-01 Real-time Process
S009 2016-03-16 30-day Notice
S008 2016-01-08 30-day Notice
S007 2015-08-13 30-day Notice
S006 2014-12-03 30-day Notice
S005 2013-08-01 30-day Notice
S004 2012-11-16 Normal 180 Day Track
S003 2012-09-20 Real-time Process
S002 2012-07-11 30-day Notice
S001 2011-12-07 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.